Vitacilina Anti Itch Hydrocortisone
NDC Package 81929-005-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Vitacilina Anti Itch Hydrocortisone is a . Marketed by Taisho Pharmaceutical California Inc., this product is identified by NDC 81929-005 and is authorized under FDA application M017.

Identification & Billing

NDC Package Code
81929-005-01
Package Description
1 TUBE in 1 CARTON / 28 g in 1 TUBE
Product Code
81929-005
11-Digit Billing Format
81929000501

Clinical Specifications

Proprietary Name
Vitacilina Anti Itch Hydrocortisone
Dosage Form
-

Regulatory & Marketing

Labeler Name
Taisho Pharmaceutical California Inc.
FDA Application #
M017
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
10-01-2024
End Marketing Date
10-02-2024
Listing Expiration
10-02-2024
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 81929-005-01 identifies a specific commercial package of 1 tube in 1 carton / 28 g in 1 tube of Vitacilina Anti Itch Hydrocortisone, labeled by Taisho Pharmaceutical California Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Taisho Pharmaceutical California Inc. on October 01, 2024. The current certification is valid through October 02, 2024.

How is this Taisho Pharmaceutical California Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 81929000501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
81929-005-01
11-Digit CMS (5-4-2)
81929-0005-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.